On Wednesday, Feb. 27, 2013, I attended an update meeting on FDA’s Patient Focused Drug Development Initiative. Last fall, I led the campaign urging FDA to include narcolepsy in this 20 disease innovative program (read more here). I testified at the FDA hearing and hundreds of narcolepsy advocates sent in comments of support.
FDA received over 4,500 comments from various disease areas. FDA will announce the chosen disease areas by the end of March and publish results in the Federal Registry.
Wednesday’s meeting explored options for how FDA might engage patient communities in the Patient-Focused Drug Development program. I enjoyed participating and representing narcolepsy in the discussion.
I truly hope narcolepsy is chosen for the FDA initiative. I will report back as soon as I get word.
For updated posts about the FDA Initiative, click here.